Anti-(integrin beta-3) human monoclonal antibody
Phase 2Terminated 2 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fetal and Neonatal Alloimmune Thrombocytopenia
Conditions
Fetal and Neonatal Alloimmune Thrombocytopenia
Trial Timeline
Nov 21, 2024 → Oct 1, 2025
NCT ID
NCT06435845About Anti-(integrin beta-3) human monoclonal antibody
Anti-(integrin beta-3) human monoclonal antibody is a phase 2 stage product being developed by Rallybio for Fetal and Neonatal Alloimmune Thrombocytopenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT06435845. Target conditions include Fetal and Neonatal Alloimmune Thrombocytopenia.
What happened to similar drugs?
0 of 2 similar drugs in Fetal and Neonatal Alloimmune Thrombocytopenia were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06435845 | Phase 2 | Terminated |
Competing Products
3 competing products in Fetal and Neonatal Alloimmune Thrombocytopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Strattera + Placebo | Eli Lilly | Phase 1 | 29 |
| Genotonorm (Somatropin) | Pfizer | Phase 3 | 40 |
| somatropin + somatropin | Sanofi | Phase 3 | 40 |